Osteoporosis in men

Journal of Orthopaedic Nursing

Volumn 5, Issue 2, 2001, Pages 73-75

  Sutcliffe, Anne M ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Male osteoporosis, osteoporotic fracture

Indexed keywords

EID: 0008375645     PISSN: 13613111     EISSN: None     Source Type: Journal    
DOI: 10.1054/joon.2000.0151     Document Type: Article

References (16)

1. Baillie S. P., Davison C. E., Johnson F. J., Francis R. M. Pathogenesis of vertebral crush factors in men. Age and Aging. 21:1992;139-141.
2. Cooper C. Epidemiology and public health impact of osteoporosis. Reid D M. Bailliere's Clinical Rheumatology. 1993;459-478 Bailliere Tindall, London.
3. Cooper C. Epidemiology and definition of osteoporosis In: Compston J. E. Osteoporosis. New perspectives on causes, prevention and treatment. 1996;1-10 Royal College of Physicians of London.
4. Dawson-Hughes B., Harris S. S., Krall E. A., Dallal E. G. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years and older. New England Journal of Medicine. 337:1997;670-676.
5. Dolan P., Torgerson D. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International. 8:1998;611-617.
6. Eastell R., Boyle I. T., Compston J. Management of male osteoporosis: Report of the UK Consensus Group. Quarterly Journal of Medicine. 91:1998;71-92.
7. Francis R. M. Cyclical etidronate in the management of osteoporosis in men. Review of Contemporary Pharmecotherapy. 9:1998;261-266.
8. Orwoll E., Ettinger M., Weiss S. Alendronate treatment of osteoporosis in men. Journal of Bone and Mineral Research. 14 (suppl 1):1999;S184.
9. Orwoll E. S., Oviatt S. K., McClung M. R., Deftos L. J., Sexton G. The rate of bone mineral loss in normal men and women and the effects of calcium and cholecalciferol supplementation. Annals of Internal Medicine. 112:1990;29-34.
10. Poor G., Atkinson E. J., Lewallen D. G., O'Fallon W. M., Melton L. J. III. Age related hip fracture in men: clinical spectrum and short term outcome. Osteoporosis International. 5:1995;419-426.
11. Poor G., Jacobsen S. J., Melton L. J. Mortality after hip fracture. Facts and Research in Gerontology. 7:1994;91-109.
12. Saag K. G., Emky R., Schnitzer T. J. Alendronate for the prevention and treatment of gluco-corticoid induced osteoporosis. New England Journal of Medicine. 339:1998;291-299.
13. Scane A. C., Francis R. M. Risk factors for osteoporosis in men. Clinical Endocrinology. 38:1993;15-16.
14. Scane A. C., Francis R. M., Johnson F. J., Davison C. E. The effects of testosterone treatment in eugonadal men with osteoporosis. Ring E FJ. Current Research in Osteoporosis and Bone Mineral Measurement 11. 1992;54 British Institute of Radiology, London.
15. Scane A. C., Francis R. M., Sutcliffe A. M., Francis M. J. D., Rawlings D. J., Chapple C. L. Case control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporosis International. 9:1999;91-97.
16. Seeman E. Osteoporosis in men. Osteoporosis International. 9 (suppl 2):1999;S97-S110.